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Abstract 
Maple Syrup Urine Disease (MSUD) is a disorder of branched-chain amino acids 
(BCAA). The defect in the branched-chain α-keto acid dehydrogenase complex activity 
lead to an accumulation of these compounds and their corresponding α-keto-acids and 
α-hydroxy-acids. Studies have shown that oxidative stress may be involved in 
neuropathology of MSUD. L-carnitine (L-car) have an important role as antioxidant 
through reducing and scavenging free radicals formation and by enhancing the activity 
of antioxidant enzymes. Our study evaluated the oxidative stress parameters, di-
tyrosine, isoprostanes and antioxidant capacity, in urine of MSUD patients on protein-
restricted diet supplemented or not with L-car capsules at a dose of 50 mg kg-1 day-1. 
We also determined the BCAAs, α-keto acids and α-hydroxy levels in urine and 
quantified the free L-car levels. Firstly, we found a deficiency of carnitine in patients 
before the L-car supplementation. Significant increases of di-tyrosine and isoprostanes, 
as well as reduced antioxidant capacity were observed in urine of MSUD patients before 
the treatment with L-car. The L-car supplementation was able to reduce the di-tyrosine 
and isoprostanes levels, as well as to increase the antioxidant capacity. We also 
quantified the BCAAs and metabolites in urine from these patients, detecting a 
significantly increase of leucine, isoleucine, α-ketoisocaproic acid, α-
hydroxyisocaproate and α-hydroxy-B-methylvalerate after 2 months of treatment, 
compared to control group. In conclusion, our results suggest that L-car may have 
additional beneficial effects in the treatment of MSUD, not only by preventing oxidative 
damage, but also by increasing the excretion of MSUD metabolites, reducing the toxic 
effects caused by their accumulation. 
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1. Introduction  
Maple Syrup Urine Disease (MSUD) is a metabolic disease caused by a severe 
deficiency of the branched-chain α-keto acid dehydrogenase complex (BCKAD) 
activity. The blockage of this pathway leads to the accumulation in tissues and body 
fluids of branched-chain amino acids (BCAA) leucine (Leu), isoleucine (Ile) and valine 
(Val) and their respective α-keto-acids, α-ketoisocaproic acid (KIC), α-keto-β-
methylvaleric acid (KMV) and α-ketoisovaleric acid (KIV), as well as the 
corresponding α-hydroxy acids, the α-hydroxyisocaproate (HIC), α-hydroxy-β-
methylvalerate (HMV) and the α-hydroxyisovalerate (HIV), respectively (Treacy et al 
1992; Chuang and Shih 2001; Harris et al 2004).  
 Based on the clinical presentation and biochemical responses to thiamine 
administration, MSUD patients can be divided into five phenotypes: classic, 
intermediate, intermittent, thiamine-responsive and dihydrolipoyl dehydrogenase (E3) 
deficient (Chuang and Shih 2001). The main signs and symptoms presented by MSUD 
patients include psychomotor delay and mental retardation, coma, convulsions, poor 
feeding, apnea, ataxia, ketoacidosis, hypoglycemia, as well as generalized edema and 
hypomyelination/demyelination evidenced by magnetic resonance imaging studies of 
the central nervous system. The worldwide frequency of MSUD is approximately 1 in 
185,000 newborns (Chuang and Shih 2001). 
The mechanisms involved in the neurological symptoms presented by MSUD 
patients are still poorly understood. However, several studies have been demonstrated 
that Leu and/or KIC are the main neurotoxic metabolites in MSUD, and the high 
concentrations of these metabolites can be associated with the appearance of 
neurological symptoms (Snyderman et al 1964; Chuang and Shih 2001). The 
metabolites accumulated in this disease provoke convulsions (Coitinho et al 2001), 
neuronal apoptosis (Jouvet et al 2000), impairment of neurotransmitter synthesis (Zielke 
et al 1997; Tavares et al 2000), myelin alteration (Treacy et al 1992) and affect energy 
metabolism in rat brain (Danner and Elsas 1989; Sgaravatti et al 2003).  
The MSUD treatment consists of a low protein diet and a semi-synthetic formula 
poor in BCAA and supplemented by essential amino acids, vitamins and minerals 
(Snyderman et al 1964; Danner and Elsas 1989; Chuang and Shih 2001; Sitta et al 
2014). However, natural protein restriction may lead to an increase of nutritional 
deficiencies and to a low total antioxidant status that contribute to oxidative stress 
(Barschak et al 2007, Barschak et al 2008; Mescka et al 2013; Sitta et al 2014). 
Oxidative stress is characterized as an imbalance between oxidants and antioxidants 
species in favor of oxidants, causing damage to many cellular constituents, such lipids, 
proteins and DNA (Finkel et al 2000; Halliwell and Gutteridge 2007). 
L-carnitine (L-car) is a highly polar quatenary amine which plays important 
metabolic functions in the organism, like transport of long-chain fatty acids across the 
inner mitochondrial membrane for utilization in β-oxidation. Furthermore, this 
compound has demonstrated antioxidant activity by reducing and scavenging free 
radicals formation and by enhancing the activity of enzymes involved in the defense 
against reactive species (Derin et al 2004; Gulcin et al 2006). It was verified that MSUD 
patients have L-car deficiency, since this compound is obtained mainly from diet 
(Mescka et al 2013; Sitta et al 2014). Recent studies have demonstrated an increase of 
plasma antioxidant status in patients with inborn errors of metabolism supplemented 
with L-car (Ribas et al 2010; Mescka et al 2011; Sitta et al 2011; Mescka et al 2013; 
Ribas et al 2014). There are no studies in literature focusing urinary amino acids, α-keto 
acids, α-hydroxy acids and oxidative stress parameters in MSUD treated patients. It is 
important to emphasize that BCAA metabolites are highly excreted in urine in this 
disease. 
Thus, in this study, it was evaluated oxidative stress parameters and BCAA, α-
keto acids and α-hydroxy acids concentrations in the urine of treated MSUD patients, 
supplemented or not with L-car. Our objective was to investigate a possible association 
between L-car, metabolites accumulation and oxidative stress in treated MSUD patients. 
 
2. Material and methods 
2.1 Patients, controls and biological samples  
In this study it was studied seven patients (mean age, at collect moment, 8.28 ± 
2.87 years) with late diagnosis and classical MSUD under protein restricted diet 
protocol from Medical Genetic Service of Hospital de Clínicas de Porto Alegre 
(HCPA), Brazil, which were diagnosed by elevated plasma BCAA levels. Whole blood 
on filter paper was used to evaluate the free L-car levels, plasma was used to amino acid 
quantification and urine samples were used to determine the parameters of oxidative 
stress and the concentrations of amino acids, α-keto acids and α-hydroxy acids. 
Dietary treatment (median 0.95 year – range 15 days to 9.83 years) consisted of 
a protein-restricted diet supplemented with a semi-synthetic formula of essential amino 
acids (except leucine, isoleucine and valine), vitamins and minerals and not containing 
L-car (MSUD 2-Milupa®). The diet contained the following amounts of Leu (before 12 
months of age: 40–80 mg kg−1 day−1; after 1 year of age: 275–535 mg day−1), Ile 
(before 12 months of age: 20–50 mg kg−1 day−1; after 1 year of age: 165–325 mg 
day−1) and Val (before 12 months of age: 20–60 mg kg−1 day−1; after 1 year of age: 
190–375 mg day−1). In addition, for this study, MSUD patients were supplemented 
with L-car capsules, fractionated and mixed with the formula, at a dose of 50 mg kg−1 
day−1, not exceeding 1.5 g day−1 for 2 months. Oxidative stress parameters, amino 
acids, α-keto acids, α-hydroxy acids and free L-car levels were analyzed in MSUD 
patients before (Group A) and after one (Group B) and 2 months (Group C) of L-car 
supplementation. The control group consisted of samples from six aged-matched 
healthy children (mean age 6.0 ± 3.12 years). The study was approved by the Ethics 
Committee of HCPA, RS, Brazil. All parents of the patients included in the present 
study gave informed consent. 
 
2.2 Amino acids determination 
The free amino acids in urine and plasma were determined by high-pressure 
liquid chromatography (HPLC) method according to Joseph and Marsden (Joseph and 
Marsden 1986). The quantification was performed by relating the chromatographic peak 
area of each amino acid to those obtained from a known standard solution and to the 
peak area of the internal standard (homocysteic acid) with known concentration. Results 
were expressed in µmol/L (plasma) and µmol/g creatinine (urine). 
 
2.3 α-Keto acids and α-hydroxy acids determination  
The α-keto acids KIC, KMV, KIV and the α-hydroxy acids HIC, HMV and HIV 
were determined in urine by gas chromatography-mass spectrometry (GC/MS) 
according to Sweetmann (Sweetmann et al 1995), using hexadecane and heptadecanoic 
acid as internal standards. The quantification was performed by relating the metabolites 
chromatographic peak area to those obtained from a known standard solution for each 
metabolite and to that of internal standard peak area. Results were expressed in µmol/L. 
 
2.4  Free L-carnitine determination 
Free L-car levels were determined in blood spots by liquid chromatography 
electrospray tandem mass spectrometry (LC/MS/MS) using the multiple reaction 
monitoring (MRM) mode (Chace et al 1997) and the results were reported in µmol/L. 
 
2.5 15-F2t-isoprostane determination 
15-F2t-isoprostane, a product of arachidonic acid metabolism and a biomarker of 
lipid peroxidation, was measure by a competitive enzyme-linked immunoassay (ELISA) 
(Oxford Biomed, EA 85), according the kit’s instructions. First, the urine samples were 
mixed with dilution buffer. In this assay, the 15-F2t-isoprostane in the urine samples 
competes with the 15-F2t-isoprostane conjugated to horseradish peroxidase (HRP) for 
the binding to a specific antibody fixed on the microplate. The concentration of 15-F2t-
isoprostane was determined by the intensity of color developed after the substrate was 
added (wavelength at 630 nm). Results were expressed as nanograms of isoprostanes 
per mg of urinary creatinine.  
 
2.6 Di-tyrosine autofluorescence determination  
Di-tyrosine (Di-tyr) content, used to determine in urine the levels of protein 
oxidation, was determined by autofluorescence, according Kirschbaum, 2002. For Di-
tyr fluorescence determination, 50 µl of thawed urine was added to 950 µl of 6 mol/L 
urea in 20 mmol/L sodium phosphate buffer pH 7.4. After 30 minutes, the concentration 
was measured using a fluorometer (excitation 315 nm, emission 410 nm). Results were 
expressed as fluorescence units per mg urine creatinine (Kirschbaum et al 2002). 
 
2.7 Antioxidant capacity determination 
The urinary antioxidant capacity was determined using a chemical assay 
(Antioxidant Assay Kit, Cayman Chemical, 709001). This assay measures the capacity 
of antioxidants in the urine to inhibit the oxidation of 2,2’-azino-di-3-
ethylbenzthiazoline sulfonate (ABTS) by metmyglobin. This reaction can be monitored 
by detecting the absorbance at 750 nm and the inhibition of the oxidation is proportional 
to antioxidants concentration. A standard curve using Trolox, a water-soluble 
tocopherol analogue, is used to calculate the capacity of the antioxidants in preventing 
the ABTS oxidation. Urinay antioxidant status was expressed as micromolar trolox 
equivalents.   
 
2.8 Statistical analyses  
Comparison between means was analyzed by Repeated Measures ANOVA 
followed by the Tukey multiple range test for parametric data and Friedman Test 
followed by Dunn's Multiple Comparison Test for nonparametric values when the F 
value was significant (P < 0.05). Correlations were carried out using the Pearson 
correlation coefficient. 
 
3. Results 
Figure 1 shows the measurement of free L-car in blood spots from MSUD 
patients, before and after the supplementation, and controls. The results demonstrated 
that MSUD patients had significantly reduced free L-car levels before the treatment 
(Group A) compared to control group. The supplementation with L-car was able to 
reverse this deficiency once it was observed a significant increase of L-car levels after 1 
(Group B) and 2 (Group C) months of treatment [F (3,19) = 6.253, P<0.05]. 
We measured the levels of Leu in plasma from MSUD patients, before and after 
the treatment, and controls. We found the follow values, expressed in µmol/L: controls 
= 130.75 ± 27.16, Group A = 178.18 ±58.59, Group B = 264.57 ± 136.74, Group C = 
278 ±105.55. Dates are represented as mean ± SD. There was no significant difference 
between groups. 
Figure 2 shows the evaluation of oxidative stress in urine from MSUD patients. 
The Figure 2A exhibits the di-tyrosine levels, a biomarker of oxidative damage to 
proteins. We verified that the Di-tyr levels before the supplementation with L-car 
(Group A) was markedly increased compared to control group, as well as after 1 month 
of treatment (Group B), and L-car therapy was able to reduce the di-tyr levels, reverting 
after 2 months of treatment (Group C). Group C was significantly different from groups 
A and B [F (3,15) = 18.45, P<0.05]. We also found a significant negative correlation 
between free L-car levels and Di-tyr levels (r = -0.557, p<0.05) (Figure 3). 
Figure 2B shows the isoprostanes levels, an end product of arachidonic acid 
peroxidation. We found a significant increase in isoprostanes levels before the treatment 
(Group A) compared to the control group and the supplementation with L-car was able 
to reduce the lipid peroxidation in treated MSUD. Groups B and C show a significant 
decrease in the isoprostanes levels compared to the Group A [F (3,16) = 4.184, P<0.05]. 
Figure 2C shows the results of urinary antioxidant capacity in the groups. We 
found that before the treatment (Group A) and after one month (Group B) with L-car 
supplementation, the patients had a significant lower urinary antioxidant capacity 
compared to control group. However, the L-car supplementation after 2 months (Group 
C) was able to revert this process to control levels [F (3,15) = 15.02, P<0.05]. 
We also measured the urinary levels of branched-chain amino acids, α-keto acids 
and α-hydroxy acids in order to evaluate the effects of L-car on this compounds (Table 
1). It was found an increase in the Leu and Ile levels in urine of patients only after 2 
months (Group C) with L-car supplementation compared to control group [F (3,19) = 
9.720, P<0.05) and F(3,20) = 9.24, P<0.05)], respectively. There was no significant 
difference between the groups for the amino acid Val.  
The urinary concentrations of KMV, KIV and HIV were not altered by L-car 
supplementation. Increased levels of α-ketoisocaproic acid (KIC) and the α-hydroxy 
acids α-hydroxyisocaproate (HIC) and α-hydroxy-B-methylvalerate (HMV) were found, 
mainly after 2 months with L-car supplementation (Group C) compared to control group 
[F(3,18) = 1,018, P<0.05), F(3,15) = 20.33, P<0.05) and F(3,11) = 9.461, P<0.05)], 
respectively. Moreover, the levels of HIC were significant different between all the 
groups tested.  
 
4. Discussion  
MSUD was first described by Menkes and colleagues in 1954 and the dietary 
treatment was implemented ten years later by Snyderman (Snyderman et al 1964; 
Chuang and Shih 2001). The aim of the MSUD treatment is to keep the BCAA plasma 
concentrations in suitable levels for patients with this disease in order to minimize the 
brain damage found in MSUD patients without treatment or in metabolic crisis (Danner 
and Elsas 1989; Chuang and Shih 2001; Wendel et al 2006). As the treatment is based 
on a BCAA-restricted formula (without L-car), containing essential amino acids, 
vitamins and minerals,  many studies have reported that MSUD patients have nutritional 
deficiency, including L-car (Mescka et al 2013), which can cause an antioxidant 
defenses impairment (Lombeck et al 1978; Borglund et al 1989; Barschak et al 2006; 
Barschak et al 2007; Barschak, et al 2008). In our study, we demonstrated that the levels 
of free L-car in MUSD patients before the treatment were significantly reduced and the 
supplementation with L-car during 1 and 2 months was able to restore the normal levels. 
Our results corroborate with other studies, demonstrating that patients treated with 
protein restrict diet could have a deficiency of carnitine (Sitta el al 2011; Sitta et al 
2014).   
Several studies have shown that the accumulated metabolites in inborn errors of 
metabolism induce excessive free radical production and reduce the tissue antioxidant 
defenses (Colome et al 2000; Barschak et al 2008; Wajner et al 2004). In this context, in 
vitro and in vivo studies have been developed in MSUD (Bridi et al 2005; Bridi et al 
2006; Barschak et al 2006; Barschak et al 2007; Barschak et al 2008; Mescka et al 
2011; Mescka et al 2013), but the oxidative stress parameters in urine of these patients 
have not been studied. In other hand, these parameters in urine have been investigated in 
some metabolic diseases. It has been reported that patients with propionic and 
methylmalonic acidurias had high levels of urinary isoprostanes, that were reversed 
after the treatment with L-car. Furthermore, patients with these acidurias had a low 
urinary antioxidant capacity (Ribas et al 2012). 
In this study, we demonstrated that MSUD patients treated with protein 
restricted diet, but without L-car supplementation, had significantly increased Di-tyr 
levels in urine compared to control group and after 2 months of L-car supplementation, 
Di-tyr concentration were reduced to the normal levels. Furthermore, we found a 
negative correlation between urinary Di-tyr and blood free L-carnitine concentrations in 
MSUD patients, indicating that L-car treatment can be involved in the prevention of 
protein oxidative damage. Di-tyr is formed by the oxidation of adjacent protein tyrosine 
residues leading to the formation of a highly stable inter-phenolic bond that does 
undergo further metabolism (Kirschbaum et al 2002). 
 Protein oxidation by reactive species can lead enzymes, receptors and transport 
proteins to malfunction and, eventually, inducing alteration of cellular metabolism 
(Halliwell and Gutteridge 2007). Our results are in agreement with other studies. It has 
been seen that in plasma of MSUD patients, there was protein damage evidenced by 
increased of carbonyls content (Mescka et al 2013). Furthermore, studies in cortex of 
rats, evaluating carbonyls and sulfhydryl content as markers of protein damage, 
demonstrated that carbonyls content was significantly enhanced in cerebral cortex in 
MSUD group while sulfhydryl content was significantly reduced, indicating the 
occurrence of oxidized proteins, and the treatment with L-car prevented these effects, 
reducing to control levels this damage (Mescka et al 2011). It is known that for other 
inborn errors of metabolism, protein damage has already been verified since the patients 
with propionic and methylmalonic acidurias presented high levels of Di-tyr in urine and 
the treatment with L-car was able to reduce this damage to control levels (Ribas et al 
2011).  
We also demonstrated that treatment with L-car was able to reduce the 
isoprostanes levels progressively after 1 and 2 months of supplementation, indicating a 
decrease in the lipid oxidation in urine. Recently, studies showed that L-car proved to 
be effective in reducing the lipid oxidation, since malondialdehyde (Mescka et al 2013) 
and thiobarbituric acid-reactive substances (Barschak et al 2006; Barschak et al 2007) 
were markedly increased in MSUD patients  and the therapy with L-car reversed 
oxidative damage to lipids in plasma of MSUD patients (Mescka et al 2013). 
Furthermore, L-car prevented lipid peroxidation in cerebral cortex of rats in a 
chemically-induced acute model of MSUD (Mescka et al 2011). L-car have been 
described in other studies as an antioxidant able to combat the lipid peroxidation (Abdul 
and Butterfield 2007; Miguel-Carrasco 2010) 
Altered antioxidant capacity in plasma from MSUD patients was observed in 
other studies that demonstrated a decreased of the total antioxidant status, which 
represents the quantity of tissue antioxidants, and of the total antioxidant reactivity, 
which reflects the tissue capacity to react with free radicals (Barschak et al 2006; 
Barschak et al 2008). Our results are also in agreement, showing a reduction of urinary 
antioxidant capacity in patients before L-car supplementation. Possibly, these alterations 
can occur because of the BCAA restrict diet, normally used in the MSUD therapy, is 
poor in micronutrients necessary for the antioxidant status (Barschak et al 2007). 
Decreased urinary antioxidant capacity may reflect a reduction of antioxidants in the 
blood, such as uric acid and dietary antioxidants. Otherwise, it was verified in our study 
that after 2 months of L-car administration, this process was reversed to control levels, 
reinforcing an important antioxidant effect of L-car in MSUD patients. 
In this study, we quantified the most accumulated metabolites in urine from 
MSUD patients. We found an increase, compared to control group, mainly after 2 
months of treatment, of the amino acids Leu and Ile and of the metabolites KIC, HIC 
and HMV. Among these compounds, Leu and KIC are considered the main neurotoxic 
agents in MUSD (Chuang and Shih 2001). The appearance of these two compounds, as 
well as HIC and HMV, in significantly high concentrations after 2 months of L-car 
treatment suggested that supplementation with this coumpond may influence the urinary 
excretion of these metabolites, decreasing the concentration in the blood and tissues. It 
should be emphasized that because the toxic effects of the accumulating metabolites in 
MSUD patients, the beneficial effects of L-carnitine supplementation, such as correction 
of carnitine deficiency and restoration of intramitochondrial acyl-CoA/CoA ratios, may 
improve the metabolic status of these patients (Ribas et al. 2014). All these factors can 
have contributed to lower levels of oxidative damage observed in MSUD patients 
during treatment with L-carnitine.  
It is important to emphasize that Di-tyr and antioxidant capacity were reversed 
only 2 months after L-car treatment. Carnitine supplementation is frequently used in 
patients with organic acidemias, as for example, propionic, methylmalonic, isovaleric, 
3-hydroxy-3-methylglutaric and glutaric type I acidemias and beneficial effects are well 
described in these patients (Hoffmann et al 1996; Bykov et al 2004; Kölker et al 2011; 
Ribas et al 2014). In these diseases, therapy with L-car is used to promote the reduction 
of the acyl Coenzyme A toxic accumulation, releasing Coenzyme A for other essential 
oxidative pathways and restoring normal concentrations in cases where there is a 
deficiency (Chalmers et al 1984). We believe that, based in these studies, the effect 
associated to L-car could be occurring in MSUD, by promoting the excretion of the 
metabolites in urine of the patients.  
In conclusion, our results demonstrated that there are damage to protein and 
lipids in urine from MSUD patients, as well as alterations in the antioxidant capacity. 
The supplementation with L-car could be involved in the prevention of oxidative 
damage to protein and lipid in MSUD since we detected a decrease of di-tyrosine and 
isoprostanes levels in urine from treated patients, as well as an improvement on the 
urinary antioxidant capacity. Furthermore, we suggest that L-car could be used in 
MSUD patients to help in the excretion of toxic metabolites, representing a new 
approach to the current treatment, which consists of protein restrict diet. In addition, the 
use of urine, easily collected, can be an option for monitoring such patients by 
evaluating the parameters of oxidative stress.  
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Legends 
Figure 1. Free L-carnitine measurement in blood spots from MSUD patients and 
controls by liquid chromatography electrospray tandem mass spectrometry 
(LC/MS/MS). Group A represents MSUD patients before treatment with L-car. Group 
B and Group C represent MSUD patients after 1 and 2 months of L-car 
supplementation, respectively.  Data represent the mean ± SD. Number of MSUD 
patients = 7-4. Number of controls = 6. * P<0.05 compared to controls, # P<0.05 
compared to Group A, § P< 0.05 compared to Group B. 
 
 
Figure 2. (A) Di-tyrosine (Di-Tyr), (B) isoprostanes and (C) antioxidant capacity 
measurements in urine from MSUD patients and controls. Group A represents MSUD 
patients before treatment with L-car. Group B and Group C represent MSUD patients 
after 1 and 2 months of L-car supplementation, respectively.  Data represent the mean ± 
SD. Number of MSUD patients = 7-4. Number of controls = 6. * P<0.05 compared to 
controls, # P< 0.05 compared to Group A, § P< 0.05 compared to Group B. 
 
 
Figure 3. Correlation between Di-tyrosine vs. Free L-carnitine levels in MSUD 
patients. Graphs show the Pearson correlation coefficient and probabilities. 
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  Tables 
Table 1. Urinary concentrations of amino acids (µmol/g creatinine), branched chain α-keto-acids and α-
hydroxy acids (µmol/L) in MSUD patients and controls. 
 
 
 
Amino acids α-Keto-acids α-Hydroxy acids 
 
Control 
Group A 
Group B 
Group C 
Leu 
32±7 
78±105 
88±58 
256±224* 
Ile 
17±3 
99±118 
56±55 
76±37* 
Val 
50±14 
139±101 
60±15 
104±36 
KIC 
0.00±0.00 
8.1±8.1 
1.7±2.5 
78±53*§ 
KMV 
0.00±0.00 
1.22±2.99 
0.15±0.39 
2.11±4.23 
KIV 
0.00±0.00 
0.42±0.77 
0.67±0.85 
14±27 
HIC 
0.00±0.00 
7±17* 
142±337*# 
63±146*#§ 
HMV 
0.00±0.00 
23±32 
10±18 
118±50*#§ 
HIV 
0.00±0.00 
74±114 
166±289 
6993±8198 
 
Values represents mean ± SD. Number of MSUD patients = 7-4. Number of controls = 6. * different to control P<0.05, 
# different to A P<0.05, § different to B P<0.05. 
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Aims and Scope 
 
The JIMD is the official journal of the Society for the Study of Inborn Errors of Metabolism, 
SSIEM. By enhancing communication between workers in the field throughout the world, the 
JIMD aims to improve the management and understanding of inherited metabolic disorders. 
It publishes results of original research and new or important observations pertaining to any 
aspect of inherited metabolic disease in humans and higher animals. This includes clinical 
(medical, dental and veterinary), biochemical, genetic (including cytogenetic, molecular and 
population genetic), experimental (including cell biological), methodological, theoretical, 
epidemiological, ethical and counselling aspects. The JIMD also reviews important new 
developments or controversial issues relating to metabolic disorders and publishes reviews 
and short reports arising from the Society's annual symposia. A distinction is made between 
peer-reviewed scientific material that is selected because of its significance for other 
professionals in the field, and non-peer-reviewed material that aims to be important, 
controversial, interesting or entertaining (“Extras”).  
 
The Journal of Inherited Metabolic Disease exists as two sister publications which are served 
by a single Editorial Team and a single manuscript submission and review process: the 
traditional print and online journal “JIMD” and the online-only “JIMD Reports”. The latter 
publishes scientifically sound research findings or clinical observations that warrant 
communication in the peer-reviewed literature but are of more limited interest to the 
readers. In addition to full electronic publication as “JIMD Reports”, the abstracts of these 
articles are also printed in the non-online section of the “JIMD” to reach the widest possible 
readership. All other types of articles are published electronically and in print in the JIMD. 
 
Scientific contributions 
Full Articles 
The JIMD welcomes scientific contributions for publication as printed full articles in the 
following categories: 
• Original Articles: Important manuscripts that may be expected to influence or change 
clinical or research practice with regard to inherited metabolic disorders. Original articles 
may include comprehensive studies on disease features in groups of patients, important 
novel information on a disease or relevant research findings. Exceptional case reports 
that are judged to be of general interest to the readers may also be accepted as original 
articles.  The editors may reject submitted manuscripts as original articles but invite 
revision or resubmission for publication as Reports in “JIMD Reports”. Anecdotal 
observations may also be submitted as “Extras”. 
• Rapid Communications: Highly competitive and timely manuscripts; please discuss this 
with the editors: editor@jimd.org. 
• Reviews: Concise summaries of metabolic pathways, specific disorders, methods, 
treatment options etc.  
• Metabolic Dissertations: The JIMD invites all researchers who have completed a Ph.D. or 
M.D. thesis in the field of inborn errors of metabolism to submit a comprehensive review 
of the topic of their thesis. The article should not focus solely on the research findings 
but should cover all relevant information in the respective field. Such reviews preferably 
(but not necessarily) have a single author (other contributors should be acknowledged) 
and will be published with a photograph of the investigator. 
All authors are invited to provide a colour picture that may be used for the front cover of the 
issue in which the article appears. 
Reports (Online Articles) 
Some manuscripts present scientifically sound research findings or clinical observations that 
are worth communicating but are of more limited interest to the readers of JIMD and may 
be sufficiently summarised in an abstract of 250 words. In order to facilitate publication of 
these types of manuscripts, “JIMD Reports” has been introduced as a sister publication of 
the traditional “JIMD”. It is an independent periodical with its own ISSN number.  
 
All manuscripts submitted as Reports to the JIMD website will be considered for “JIMD 
Reports” rather than for the traditional journal. They will undergo the same review process 
as Original Articles (and in exceptional cases may be reassigned for publication in “JIMD”). In 
addition, the Editorial Team (based on the advice of reviewers and Communicating Editors) 
may reject Original Articles for publication in the traditional “JIMD” but offer publication in 
“JIMD Reports”. After acceptance, articles in “JIMD Reports” are professionally typeset in the 
same manner as articles in “JIMD”, and full documents are available online to SSIEM 
members and institutional subscribers via the Springer website. JIMD Reports are submitted 
to PubMedCentral and are listed in PubMed as well as in other abstracting and indexing 
services. After an embargo period of 12 months all paperspublished in JIMD Reports are 
available as free access articles on PubMed Central, thereby ensuring widest possible 
readership. In addition, the titles and abstracts of all Reports are printed in the print-only 
“Extras” section of “JIMD”. It is recommended that authors make use of the full allowance of 
250 words for the abstract of their Reports to convey the message of the article to the 
readers of "JIMD".  
 
Reports follow the same rules as Full Articles; they should not be used as a form of 
preliminary communication. They may take the form of Research Reports, with content 
similar to that of original articles, or Case Reports. Case reports will only be considered when 
they highlight some unusual or previously unrecorded feature relevant to the disorder, or 
serve as an important reminder of clinical or biochemical features of a Mendelian disorder. 
Chance associations of two conditions or sporadic cases from new geographical locations (as 
opposed to systematic epidemiological studies) are not in themselves of sufficient scientific 
merit to justify publication.  
Images in Metabolic Medicine 
The Editors will consider clear and interesting clinical pictures or other types of images (e.g. 
laboratory results or observations) submitted with a descriptive paragraph of up to 250 
words. Prints, slides, or electronic copy are all acceptable. Authors must obtain informed 
consent for publication of patient-related materials. Case reports or additional information 
may be added as supplementary material. Images will be fully printed; title and author(s) will 
be listed in bibliographical databases such as Medline. 
Editorials 
The JIMD invites communicating editors and reviewers of articles that have been accepted 
for publication in the JIMD to provide an editorial that places the article in a broader 
context. Editorials have no abstract, may be comprised of up to 500 words and should 
contain no more than two (if any) references. Additional material can be added as 
supplementary material online. Editorials will be fully printed; title and author(s) will be 
listed in bibliographical databases such as Medline. 
Letters, Clinical/Research Observations 
The JIMD invites comments on previously published articles in the journal which should 
reach the editorial office within 4 weeks of publication of the original item. Correspondence 
may be subjected to peer-review and counter-replies are usually invited from the authors of 
the original publication.  
 
The concise form of a letter may also be used to report exceptionally important clinical or 
research observations unrelated to a previous JIMD publication that merit communication 
but do not fulfil the requirements for scientific articles or short reports. These items will be 
peer reviewed and if accepted will be pubished under the heading “Observation”.  
 
Letters should have no more than five authors. They have no abstract, are limited to a 
maximum of 500 words and should contain no more than two (if any) references. Additional 
material can be added as supplementary material online. Letters will be fully printed; title 
and author(s) will be listed in bibliographical databases such as Medline. 
 
 
Extras in the JIMD 
 
The Editors of the JIMD invite submission of short items that are interesting, stimulating, 
important or entertaining to professionals working in the field of inborn errors of 
metabolism. These items will not usually be reviewed outside the editorial board and usually 
will not be referenced in bibliographic databases. All items of this type should be submitted 
by Email to the editorial office (editor@jimd.org); please provide full personal details for all 
authors of each contribution. 
Fillers 
Small texts that are used to fill gaps, e.g. at the end of original articles, have been a long and 
cherished tradition in some journals. They usually have the added advantage of entertaining 
readers and stimulating thought. The Editors invite interesting stories or personal 
experiences of up to a few hundred words on topics such as: 
• A patient / paper / experience that changed my practice  
• A memorable patient / experience 
• An error that proved educational or informative for lab operation or clinical care  
• How I embarked on this career path, and lessons learned along the way 
• Any other story conveying instruction, pathos, or humour  
 
If the filler refers to an identifiable person, written consent for publication from that person 
or an appropriate relative is required. 
Book Reviews 
Instructive reviews of up to 400 words are invited on new books published in the field of 
inborn errors of metabolism, or closely affiliated areas. 
Obituaries 
The Editors of the JIMD strongly encourage submission of obituary notices for all recently 
deceased SSIEM members or other persons in the field of inborn errors of metabolism. 
Obituary notices should be mailed to the editorial office. Please give your name and contact 
details, including a phone number and email address. Obituaries will be considered by the 
editorial board and may be shortened; they will be published (without proofs) with the name 
of the person(s) who submitted the notice.  
 
Please provide: 
1. The full name of the deceased 
2. A photograph 
3. A summary of Important data:  
a. (Last) professional position and title, place of work  
b. Date and place of birth 
c. Primary degree with university and year when obtained 
d. Additional professional qualifications with university and year when obtained 
e. Date of death, Cause of death 
4. The main text summarising important contributions and personal characteristics of 
the deceased. The last sentence should state the remaining relatives such as spouse 
and/or the number of children and grandchildren. 
 
Instructions for Submission  
Material submitted to the JIMD (incl. JIMD Reports) must conform to the uniform 
requirements for manuscripts submitted to biomedical journals as outlined by the 
International Committee of Medical Journal Editors (http://www.icmje.org/index.html); see 
also International Committee of Medical Journal Editors (1999) Med Educ 33: 66-78.  
Online Submission  
All scientific contributions for publication in the JIMD (including JIMD Reports) must be 
submitted by the web-enabled online manuscript submission and review system. As the 
review process is also fully web-based, this system allows editors to keep review times as 
short as possible and offers authors the option to track progress of the review of their 
manuscripts. The online manuscript submission and review system for the Journal of 
Inherited Metabolic Disease offers easy and straightforward log-in and submission 
procedures. Please refer to:  
www.editorialmanager.com/boli  
The system supports a wide range of submission file formats for manuscripts (Word, 
WordPerfect, RTF, TXT and LaTex) and figures (TIFF, EPS, Microsoft® Office formats and 
Postscript). PDF is not an acceptable file format.  
If you encounter any difficulties while submitting your manuscript online, please contact the 
responsible Editorial Assistant by clicking on "CONTACT US" from the tool bar.  
General Rules  
It is a condition of acceptance that all articles have not been and will not be published 
elsewhere in substantially the same form. The submitting author must have circulated the 
article and secured final approval of the version to be peer-reviewed from all co-authors 
prior to article submission. This includes confirmation of  
• absence of previous similar or simultaneous publications,  
• their inspection of the manuscript,  
• their substantial contribution to the work (all authors should have been involved in (a) 
conception and design, or analysis and interpretation of data, and (b) drafting the article 
or revising it critically for important intellectual content)  
• their agreement to submission.  
 
It should be noted that these conditions are later confirmed in writing by the corresponding 
author in a copyright transfer form at the time of acceptance. Publication elsewhere, at any 
time, of a similar article perhaps only differing in some aspects of data, especially if the JIMD 
article is not cross-referenced, may justify formal retraction at a later date.  
Supplementary (internet-only) material may be published for all articles; we encourage or 
request deposition of raw data when this appears appropriate.  
The following information will be required at the time of online manuscript submission 
and need to be summarized under a separate section on the third manuscript page 
under “Compliance with Ethics Guidelines”.  
 
Conflict of Interest: 
The Conflict of Interest statements should list each author separately by name: 
John Smith declares that he has no conflict of interest. 
Paula Taylor has received research grants from Drug Company A. 
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If multiple authors declare no conflict, this can be done in one sentence: 
John Smith, Paula Taylor, and Mike Schultz declare that they have no conflict of interest. 
With regard to the mandatory submission of the Conflict of Interest Disclosure Form, please 
see the following section on “Competing Interests.”  
 
Informed Consent 
For studies with human subjects include the following: 
All procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients 
for being included in the study. 
Proof that informed consent was obtained must be available upon request  
If doubt exists whether the research was conducted in accordance with the Helsinki 
Declaration, the authors must explain the rationale for their approach, and demonstrate that 
the institutional review body explicitly approved the doubtful aspects of the study. 
 
If any identifying information about patients is included in the article, the following sentence 
should also be included: 
Additional informed consent was obtained from all patients for which identifying information 
is included in this article. 
 
Animal Rights 
For studies with animals include the following sentence: 
All institutional and national guidelines for the care and use of laboratory animals were 
followed. 
 
For articles that do not contain studies with human or animal subjects performed by any of 
the authors, please include the following sentence: 
This article does not contain any studies with human or animal subjects performed by the any 
of the authors. 
 
Details of the contributions of individual authors 
Please make clear who has contributed pertinent aspects of the planning, conduct, and 
reporting of the work described in the article.  
 
Competing Interests  
Conflict of interest exists when an author (or the author’s institution), reviewer, or editor has 
financial or personal relationships that inappropriately influence (bias) his or her actions 
(such relationships are also known as dual commitments, competing interests, or competing 
loyalties). These relationships vary from those with negligible potential to those with great 
potential to influence judgment, and not all relationships represent true conflict of interest. 
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